This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jazz Pharma Still Making Investors Sing

NEW YORK (TheStreet) -- At the end of 2013, Jazz Pharamecuticals (JAZZ - Get Report) announced the acquisition of Gentium. Both are among my stock picsk. Jazz has blasted off to new highs since news of the merger.

I have liked Jazz for a long time now. It has done very well so far. But what now?

Data from Best Stocks Now App

Jazz Pharmaceuticals is a nearly $9 billion mid-cap specialty biopharmaceutical company that focuses on the identification, development and commercialization of products for narcolepsy, oncology, pain and psychiatry.

Must Read: The Business of The Beatles Keeps Booming 50 Years After Taking America by Storm


Over the past five years, the stock has made beautiful music. It is one of the best performers of any stock that I track.

Data from Best Stocks Now App

Jazz has averaged an astounding 175% per year over the last five years, while the S&P 500 averaged only 16.6% during that same time frame. Over the last three years, Jazz has delivered 89%. The S&P delivered 11.5% returns to investors. Over the last 12 months, Jazz is up 164%, while the S&P is up only 19%.

However, Jazz is a very aggressive stock. Note that it was down a nauseating 87% in 2008. Hence my safety grade of D for it.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
JAZZ $133.03 0.00%
AAPL $109.50 0.00%
FB $92.47 0.00%
GOOG $639.16 0.00%
TSLA $226.72 0.00%


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs